Latest News

25 February 2020

Cytox MedNous coverage: Genetic risk assessment in Alzheimer's disease

Dr Alex Gibson, Business Development Officer at Cytox discusses in MedNous how to predict a person’s genetic risk of developing Alzheimer's using Polygenic Risk Scores. First application is identifying patients most suitable to enter clinical trials, based on risk of significant cognitive decline.

Cytox GeneticRiskADAlexGibson Feb 2020

From our portfolio

Blueberry Therapeutics


Blueberry Therapeutics is a biotechnology company developing a range of anti-microbial products u...

viewview our portfolio

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200